<qa>  What is the aim of this study?The aim of this study is to determine whether alternating courses of cyclophosphamide, doxorubicin, vincristine, prednisonedexamethasone, cytarabine, cisplatin CHOPDHAP plus rituximab followed by total body irradiation TBIhigh dose cytarabine ARA-Cmelphalan-peripheral blood stem cell transplantation TAM-PBSCT can improve the time to treatment failure compared to CHOP plus rituximab followed by standard PBSCT dexamethasone, carmustine, cytarabine, etoposide, and melphalan Dexa-BEAMTBIhigh dose cyclophosphamide in patients with untreated mantle cell lymphoma. 